Thrombolex
Thrombolex designs, develops, manufactures, and distributes FDA-cleared BASHIR Endovascular Catheters for treating arterial and venous thromboembolic conditions, with a primary focus on acute pulmonary embolism. The commercial-stage medical device company sells directly to U.S. hospitals and Pulmonary Embolism Response Teams.
- Company typePrivate
- Founded2016
- HeadquartersNew Britain, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Thrombolex does
Thrombolex is a commercial-stage medical device company founded in 2016 as a spin-out from Temple University, headquartered in New Britain, Pennsylvania, and incorporated in Delaware. The company designs, develops, manufactures, and distributes endovascular catheters used to treat arterial and venous thromboembolic (A+VTE) conditions, with a primary focus on acute pulmonary embolism (PE) and deep vein thrombosis (DVT). Its customers are U.S. hospitals equipped with interventional cardiology, interventional radiology, and vascular surgery capabilities, including Pulmonary Embolism Response Teams (PERT), reached through direct field sales and a group purchasing agreement with Premier Inc.
The company's core technology is the BASHIR Endovascular Catheter platform—a hybrid pharmaco-mechanical lysis (PML) system that uses an expandable infusion basket with six mini-infusion catheters to mechanically fragment thrombus while delivering targeted thrombolytics into the clot. The platform underpins eight FDA-cleared device variants, including the standard BASHIR, BASHIR S-B (designed for shorter, more tortuous vessels), BASHIR Plus (for extensive thrombus burden with variable infusion shaft lengths), and 0.035" guidewire-compatible BASHIR .035 and BASHIR S-B .035 versions. The clinical value proposition rests on a single-session "On-The-Table" protocol that avoids post-procedure thrombolytic infusion, reduces ICU utilization, and shortens hospital length of stay, with peer-reviewed evidence from the RESCUE, RESCUE-II, and RAPID-PE studies supporting the claims.
Thrombolex generates revenue through hardware sales of its catheters to hospitals and healthcare facilities, with no capital equipment requirements for adopters and pricing not publicly disclosed. Its go-to-market combines direct enterprise sales to interventional specialists, clinical evidence generation at academic medical centers (Emory, Temple, Mass General, UCLA, Mount Sinai, etc.), publications in journals such as JACC: Cardiovascular Interventions and JACC: Advances, and presentations at major interventional conferences (TCT, SIR, VIVA, VEINS, American Venous Forum). As of early 2026, Thrombolex had raised roughly $58M in cumulative equity and grant funding (including a $50M Series A led by OrbiMed in March 2026), employed 11–50 staff, and operated exclusively in the United States.
Thrombolex firmographics
Firmographics- Name
- Thrombolex
- Legal name
- Thrombolex Inc.
- Website
- https://thrombolex.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Thrombolex designs, develops, manufactures, and distributes FDA-cleared BASHIR Endovascular Catheters for treating arterial and venous thromboembolic conditions, with a primary focus on acute pulmonary embolism. The commercial-stage medical device company sells directly to U.S. hospitals and Pulmonary Embolism Response Teams.
- Ownership category
- akta.pro rank
Thrombolex industry classification
Industry- Product category
- Interventional Vascular Medical Devices
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industries
- Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE), Peritoneal Dialysis (PD) Systems & Supplies (HLAHAKAB), Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)
Keywords
Where Thrombolex is headquartered
LocationHeadquarters
- HQ city
- New Britain
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Thrombolex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations
Revenue model
- Medical Device Sales: Sale of FDA-cleared BASHIR Endovascular Catheters and related products to hospitals and healthcare facilities for treatment of VTE conditions. Multiple device variations (standard, S-B, Plus) provide upsell opportunities.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Thrombolex product offering
Product offeringCore offering
Thrombolex designs, develops, manufactures, and distributes FDA-cleared BASHIR Endovascular Catheters used to treat arterial and venous thromboembolic (A+VTE) conditions such as pulmonary embolism (PE) and deep vein thrombosis (DVT). The catheters combine mechanical clot fragmentation via an expandable infusion basket with targeted, low-dose thrombolytic delivery to restore blood flow in a single session. The product family includes the standard BASHIR, BASHIR S-B (short basket), BASHIR Plus (variable shaft infusion lengths), and 0.035" guidewire compatible variants.
Product overview
Thrombolex is a medical device company that designs, develops, and distributes innovative endovascular catheters for the treatment of arterial and venous thromboembolic (A+VTE) conditions. The company markets multiple FDA-cleared devices based on the BASHIR™ Endovascular Catheter platform technology. The product family includes the core BASHIR™ Endovascular Catheter (for peripheral and pulmonary vessels), the BASHIR™ S-B variant (for shorter, more tortuous vessels), and the BASHIR™ Plus variant (for extensive thrombus burden with variable shaft infusion lengths). All catheters use a unique hybrid mechanism combining mechanical clot fragmentation via an expandable infusion basket with pharmacological thrombolytic delivery. The company also offers 0.035" guidewire compatible versions. Devices are available in 7F and 8F sizes.
Differentiator
Problem solved
Functional benefit
Brands
- BASHIR™ Endovascular Catheter: Family of endovascular catheters using pharmaco-mechanical lysis (PML) for treatment of arterial and venous thromboembolic conditions. Includes BASHIR, BASHIR S-B, and BASHIR Plus variants.
- BASHIR™ S-B Endovascular Catheter
- BASHIR™ Plus Endovascular Catheter
Products and services
- BASHIR Endovascular Catheter Core BASHIR catheter with expandable infusion basket containing 6 mini-infusion catheters that mechanically fragment thrombus and deliver targeted thrombolytics. Available in 7F and 8F sizes for restoring blood flow in peripheral and pulmonary vessels. Intended for interventional cardiologists, radiologists, and vascular surgeons treating PE and DVT.
- BASHIR S-B Endovascular Catheter Short-basket variant of the BASHIR catheter designed for navigation and implementation in shorter, more tortuous peripheral and pulmonary vessels. Available in 7F and 8F sizes. Targeted at PE and DVT cases with challenging anatomy.
- BASHIR Plus Endovascular Catheter
- BASHIR .035 Endovascular Catheter 0.035" guidewire-compatible version of the BASHIR Endovascular Catheter for treatment of acute pulmonary embolism, offering ease of placement and shorter procedure times.
- BASHIR S-B .035 Endovascular Catheter 0.035" guidewire-compatible version of the S-B Endovascular Catheter for treatment of acute pulmonary embolism in shorter, tortuous vessels.
Quantifiable outcome
- 32.1% reduction in RV/LV diameter ratio at 48 hours (RESCUE interim analysis)
- +7 more outcomes
Companies that use Thrombolex
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles1 record
Thrombolex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Thrombolex partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AidoccoreStrategic partnership announced July 2024 to advance acute pulmonary embolism treatment through combined medical device and AI technology. The collaboration leverages Aidoc's FDA-cleared PE imaging AI to accelerate patient identification and enrollment for Thrombolex's RAPID-PE clinical study evaluating the BASHIR Endovascular Catheters.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Thrombolex competitors and assessment
Company assessmentDirect peers
- Inari Medical: Direct peer developing the FlowTriever mechanical thrombectomy system for pulmonary embolism and VTE. Acquired by Stryker in 2024 for ~$4.9B. Closest direct competitor to Thrombolex in the PE interventional space, with overlapping physician customer base (interventional cardiologists, radiologists, vascular surgeons) and PERT targeting.
- Penumbra: Direct peer with the Indigo Aspiration System for mechanical thrombectomy in PE, DVT, and peripheral vessels. Public company with substantially greater resources and broader neurovascular portfolio. Targets the same interventionalist customer base for VTE interventions.
- AngioDynamics: Direct peer offering the AlphaVac mechanical thrombectomy system for PE treatment, plus a broader portfolio of vascular access and oncology devices. Comparable PE-focused commercial effort with established but smaller-scale sales infrastructure.
Broad incumbents
- Boston Scientific (EKOS): Acquired EKOS Corporation, maker of the EKOS ultrasonic acoustic pulse thrombolysis system for PE. Large diversified medtech incumbent with substantially greater commercial scale and ICU/cardiovascular salesforce reach. Offers overlapping PE capability as part of a much broader portfolio.
- Stryker: Acquired Inari Medical in 2024, bringing FlowTriever and broader neurovascular thrombectomy capabilities into a diversified medtech portfolio. Large incumbent with unmatched scale in interventional sales coverage and hospital contracting leverage.
- Medtronic: Diversified medtech incumbent with peripheral vascular and coronary catheter portfolios serving interventional cardiologists and radiologists. While not primarily a PE thrombectomy competitor, overlaps in interventional cardiology customer relationships and broader VTE management.
- Abbott Vascular: Major diversified medtech incumbent with vascular and structural heart catheter portfolios. While not directly competing in mechanical PE thrombectomy, addresses the same interventional cardiology/radiology customer base and has the resources to enter the space.
- Teleflex: Established medtech company with interventional and vascular access product lines, including catheter-based products targeting similar hospital departments. Broader portfolio but smaller direct overlap with PML-specific positioning.
- Johnson & Johnson (Biosense Webster / Cerenovus): Diversified healthcare giant with interventional cardiology and neurovascular catheter portfolios. Co-founder Marvin Woodall has prior background at J&J Interventional Systems, signaling the relationship. While not a focused PE player, has the resources and customer reach to enter the space.
Emerging players
- Walk Vascular: Emerging competitor in mechanical thrombectomy with the JETi system for peripheral and pulmonary applications. Smaller, earlier-stage player with focused PE/DVT offerings and overlapping physician customer targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks1 record
Key highlights7 records
Customer concentration
Thrombolex social profiles
Digital presenceThrombolex compliance and trust
Trust signalCompliance2 records
Thrombolex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Thrombolex leadership team
Management profileNumber of profiles
Profiles10 records
Thrombolex funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Thrombolex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Thrombolex
What does Thrombolex do?
Thrombolex designs, develops, manufactures, and distributes FDA-cleared BASHIR Endovascular Catheters used to treat arterial and venous thromboembolic (A+VTE) conditions such as pulmonary embolism (PE) and deep vein thrombosis (DVT). The catheters combine mechanical clot fragmentation via an expandable infusion basket with targeted, low-dose thrombolytic delivery to restore blood flow in a single session. The product family includes the standard BASHIR, BASHIR S-B (short basket), BASHIR Plus (variable shaft infusion lengths), and 0.035" guidewire compatible variants.
Is Thrombolex a public or private company?
Thrombolex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Thrombolex founded?
Thrombolex was founded in 2016. It employs 11 to 50 people.
Where is Thrombolex based?
Thrombolex is headquartered in New Britain, United States, in the North America region.
How does Thrombolex make money?
One revenue line is on record: medical Device Sales.
Who are Thrombolex's main competitors?
Direct peers on record are Inari Medical, Penumbra and AngioDynamics. Broad incumbents are Boston Scientific (EKOS), Stryker, Medtronic, Abbott Vascular, Teleflex and Johnson & Johnson (Biosense Webster / Cerenovus). Walk Vascular is listed as an emerging player.
Does Thrombolex have an API?
No public API is recorded for Thrombolex.
What industry is Thrombolex in?
Thrombolex's product category is Interventional Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories). Its NAICS code is 62151 and its SIC code is 3841.